Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US8691231B2 · kind B2 · utility
6Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2012 |
| Grant date | Apr 8, 2014 |
| Priority date | — |
| Expiry date | Jun 4, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.